Biogen vs AbbVie: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Biogen Inc (BIIB)

Q3 202629 Jun – 22 Sep 2026

▼3▲1

Biogen's mixed quarter: Leqembi approvals offset trial miss and guidance cut

Leqembi approvals expand access The FDA approved at-home subcutaneous Leqembi, and China and Japan approved injections, making the Alzheimer's drug easier to use. Leqembi sales rose 15% to about $184 million, helping Q2 results beat expectations.
This is a key positive development that drove investor optimism and revenue growth.
Diranersen trial failure Biogen's experimental drug diranersen missed its main trial goal, causing shares to drop 9%. This setback raised concerns about the company's pipeline and future growth prospects.
This was a major negative event that directly impacted the stock price.
Guidance cut on acquisition charges Biogen cut its 2026 earnings guidance to $12–$13 per share due to about $3.85 per share in acquisition charges, including from the $5.6 billion Apellis buyout. This lowered profit expectations.
The guidance cut is a significant negative factor that weighed on the stock.
Medicare pricing pressure on ZURZUVAE Medicare pricing pressure may limit the launch of ZURZUVAE, and Biogen is restricting it to a few European countries. This could slow the drug's uptake and revenue potential.
This highlights a regulatory and pricing challenge that could hinder growth.

August 202629 Jun – 22 Sep 2026

▲3▼1

Biogen expands Alzheimer's reach but pricing and competition weigh

RayThera acquisition adds immunology drug Biogen acquired RayThera, gaining an early-stage immunology drug. This adds a new potential treatment to its pipeline, showing progress in building future growth beyond its current medicines.
New acquisition expands pipeline, a key positive development in the period.
China and Japan approve at-home Leqembi injections China and Japan approved at-home under-the-skin Leqembi injections, making Alzheimer's treatment easier and expanding the market. This could boost sales and patient access in key regions.
Geographic expansion of Leqembi is a new positive catalyst for demand.
Ten Phase 3 programs promise growth Biogen has ten late-stage programs in development, which could drive future growth as its multiple sclerosis revenue shrinks. This shows a strong pipeline to replace older products.
Pipeline strength is a forward-looking positive not previously highlighted.
Medicare pricing pressure may limit ZURZUVAE launch Medicare pricing pressure could hurt the launch of ZURZUVAE, and Biogen is limiting it to a few European countries. This adds risk to a key new product's sales potential.
New pricing and launch risk for ZURZUVAE is a negative factor.

Latest29 Jun – 22 Sep 2026

▲3▼1

Biogen's pipeline push and Leqembi rollout drive gains, but pricing risks loom

10 Phase III programs signal growth beyond MS Biogen said it has 10 late-stage trials with results starting in Q4, shifting focus from its shrinking MS business to new drugs like LEQEMBI and ZURZUVAE. This raises hopes for future revenue growth, supporting the stock.
This is the main new strategic update that could drive long-term growth and investor optimism.
Japan approves at-home Leqembi injection Japan cleared a subcutaneous form of Leqembi, allowing weekly at-home dosing instead of hospital infusions. This is the third country to approve it, making the Alzheimer's drug easier to use and expanding its market, which could boost sales.
New regulatory approval directly expands the addressable market for a key growth drug.
Medicare price crackdown may limit Zurzuvae launch A study warns that U.S. efforts to align Medicare drug prices with cheaper countries could push companies to raise prices or withdraw medicines elsewhere. Biogen's CEO said Zurzuvae will launch in only a few European countries to offset lost U.S. revenue, signaling a hit to its global sales potential.
This is a new regulatory risk that could reduce future revenue from a key product.
Biogen posts best quarterly revenue beat in group Biogen's Q2 revenue of $2.74 billion rose 3.4% and beat expectations by 12.1%, the strongest among 11 therapeutics stocks. This shows better-than-expected commercial execution, which can lift investor confidence.
New earnings data confirms strong performance relative to peers, a positive fundamental signal.

6 Aug – 4 Sep 2026

▲3

Biogen's mixed quarter: raised revenue, cut EPS, new China approval

RayThera acquisition closes, EPS guidance cut Biogen completed its purchase of RayThera, adding an early-stage immunology drug. But acquisition charges forced it to slash 2026 adjusted EPS guidance to $12–$13 from $14.25–$15.25. The revenue outlook rose to mid-single-digit growth, but the profit hit is what investors will feel near-term.
This is the single biggest new event, directly changing Biogen's earnings outlook and explaining the stock's mixed reaction.
China approves at-home LEQEMBI injection China approved a subcutaneous (under-the-skin) form of LEQEMBI for early Alzheimer's, allowing weekly at-home dosing instead of hospital infusions. This is the second country to clear it, after the U.S. in July. It widens the market and makes treatment far easier for patients.
A new regulatory approval in a huge market (17 million early Alzheimer's patients in China) directly boosts the long-term sales potential of Biogen's key Alzheimer's drug.
Five Phase 3 readouts ahead; shares seen as undervalued Biogen raised its non-GAAP EPS guidance and has five late-stage trial results coming in lupus, transplant and rare diseases. Shares trade about 10% below the average analyst target, with a 54% one-year total return. But competition in MS and Alzheimer's, plus launch risks for LEQEMBI and ZURZUVAE, remain real concerns.
This gives the forward-looking catalyst picture and the valuation gap, which is central to why investors are watching Biogen now.
Biogen adopts Veeva's AI-powered CRM globally Biogen selected Veeva's Vault CRM suite, an AI-driven sales and safety platform, for global use. This is an operational upgrade, not a direct revenue driver, but it signals Biogen is investing in modern commercial infrastructure. It also deepens a multi-year software relationship, which can lower long-term selling costs.
It shows Biogen is modernizing its commercial operations with AI, a modest but real positive for efficiency and execution.

July 20262 Jul – 29 Jul 2026

▲2▼2

Biogen's mixed July: Leqembi wins, diranersen disappoints, guidance cut

FDA approves at-home subcutaneous Leqembi The FDA approved Leqembi Iqlik, an at-home under-the-skin version of Biogen's Alzheimer's drug. This should make treatment easier and more convenient, potentially boosting demand and future sales.
This is a new regulatory approval that could drive future revenue growth.
Q2 results beat on rare-disease and Leqembi demand Biogen's second-quarter results beat expectations, helped by strong demand for rare-disease drugs and Leqembi, with Leqembi sales up 15% to about $184 million. This shows the company's newer products are gaining traction.
This is new financial data showing better-than-expected performance.
Diranersen trial misses goal, shares drop 9% Biogen's experimental Alzheimer's drug diranersen missed its main trial goal, with a puzzling result: the lowest dose worked best while higher doses did worse. The failure sent shares down about 9%.
This is a major clinical setback that directly hurt the stock.
2026 earnings guidance cut on acquisition charges Biogen lowered its 2026 adjusted earnings forecast to $12–$13 per share from $14.25–$15.25, due to about $3.85 per share in acquisition charges, including 85 cents from the $5.6 billion Apellis buyout.
This is a new guidance cut that weighs on investor expectations.

2 Jul – 29 Jul 2026

▲3▼1

Biogen beats on drug demand but cuts 2026 profit outlook

Q2 beat on rare-disease and Leqembi demand Biogen's second-quarter profit and revenue beat expectations, helped by strong sales of rare-disease medicines and a 15% rise in Leqembi sales to about $184 million. This shows the core business is growing, which supports the stock.
This is the main new event of the period and directly explains why Biogen is moving.
2026 profit guidance cut on Apellis charges Biogen slashed its 2026 adjusted earnings forecast to $12–$13 per share from $14.25–$15.25, largely due to $3.85 per share of acquisition-related charges, including 85 cents from the $5.6 billion Apellis buyout. This weighs on the stock.
This is the key counterweight that explains why the stock isn't rising more despite the earnings beat.
Leqembi real-world data and sales momentum A real-world study showed over 75% of early Alzheimer's patients remained stable on Leqembi, and Q2 sales grew 43% excluding one-time stockpiling. This supports adoption and future sales, a positive for Biogen as Eisai's partner.
This new evidence reinforces the commercial case for Biogen's key Alzheimer's drug.
Pipeline progress: Gazyva priority review, litifilimab enrollment The FDA granted priority review to Gazyva for a rare kidney disease, and Biogen's lupus drug litifilimab completed Phase III enrollment with results due in H2 2026. These advance the pipeline and offer future growth, supporting the stock.
These are new regulatory and clinical milestones that add to the long-term growth story.

13 Jul – 15 Jul 2026

▲3▼1

Leqembi at-home approval lifts Biogen, but diranersen dosing flaw triggers sell-off

FDA approves at-home subcutaneous Leqembi The FDA approved Leqembi Iqlik, a once-weekly under-the-skin injection for early Alzheimer's, allowing at-home dosing. This removes the need for IV infusions, which should boost patient demand and sales. Biogen shares rose on the news.
This is a major new approval that directly expands the market for Biogen's key Alzheimer's drug.
Diranersen shows 42% cognitive decline slowdown Biogen presented Phase 2 data showing its tau-targeting drug diranersen slowed cognitive decline by 42% on one measure and cut tau tangles. This suggests a potential new Alzheimer's treatment, lifting hopes for future growth.
Positive efficacy data from a new drug candidate is a key driver of investor optimism.
Dosing paradox clouds diranersen data, stock tumbles The same Phase 2 trial missed its main goal because the lowest dose worked best while higher doses did worse. This unexplained 'dosing paradox' raised doubts about the drug's effectiveness and path forward, causing Biogen shares to fall nearly 9%.
This negative twist directly caused a sharp sell-off and creates uncertainty about a key pipeline asset.
Truist upgrade highlights Alzheimer's pipeline A Truist analyst upgrade pointed to optimism for Biogen's Alzheimer's pipeline, helping the stock gain even as the broader market fell. This analyst view reinforced positive sentiment around the company's Alzheimer's efforts.
Analyst upgrade is a fresh catalyst that supported the stock price during the period.

Q2 202617 Jun – 26 Jun 2026

▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.
This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.
FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.
This is a new regulatory win that supports the bull case for Biogen's pipeline.
Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.
This is a new negative event that introduces regulatory and legal uncertainty.
Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.
This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

June 202617 Jun – 26 Jun 2026

▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.
This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.
FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.
This is a new regulatory win that supports the bull case for Biogen's pipeline.
Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.
This is a new negative event that introduces regulatory and legal uncertainty.
Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.
This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

17 Jun – 26 Jun 2026

▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.
This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.
FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.
This is a new regulatory win that supports the bull case for Biogen's pipeline.
Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.
This is a new negative event that introduces regulatory and legal uncertainty.
Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.
This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

AbbVie Inc (ABBV)

Q3 20266 Jul – 1 Oct 2026

▲2▼2

AbbVie Q3: Earnings Beat, Pipeline Wins, But Pricing and Trial Setbacks

Strong Q2 Earnings and Raised Guidance AbbVie's Q2 EPS and revenue beat estimates, and the company raised full-year revenue guidance. Skyrizi and Rinvoq now make up over 47% of revenue, offsetting Humira's decline. Neuroscience guidance also increased to about $12.7 billion.
This shows the core business outperformed and management is optimistic about future growth.
Pipeline Progress and New Approvals AbbVie reported Phase 3 successes, received EU approvals, and gained FDA approval for JUVMO. These advances strengthen the company's drug portfolio and future revenue potential.
New drug approvals and trial wins are key drivers of long-term growth and investor confidence.
EPCORE DLBCL-1 Trial Miss and Guidance Cut The EPCORE DLBCL-1 trial missed its endpoint, leading AbbVie to cut profit guidance. The stock dropped 4% on the news, highlighting pipeline risks.
This was a major setback that directly hurt earnings expectations and investor sentiment.
Pricing Pressures and Competitive Threats Trump demanded U.S. price cuts, and J&J's oral psoriasis pill won Chinese approval. Apogee's $10.9 billion acquisition will dilute earnings until 2032, and oncology sales fell 2.8% as Imbruvica dropped 27.1%.
These factors create headwinds for revenue and profitability, weighing on the stock.

September 20263 Sep – 1 Oct 2026

▲2▼2

AbbVie's Pipeline Wins Offset Apogee Dilution and Oncology Decline

Pipeline Momentum AbbVie reported multiple Phase 3 wins: etentamig for myeloma, Qulipta for menstrual migraine, and RINVOQ for vitiligo. EU approved Rinvoq for juvenile arthritis, and the FDA approved JUVMO for Parkinson's. Early-stage data for zumilokibart and ABBV-295 also showed promise.
These pipeline successes signal future growth and strengthen AbbVie's competitive position.
Neuroscience Guidance Raised AbbVie raised its neuroscience revenue guidance to about $12.7 billion, with total revenue near $67.6 billion. This reflects confidence in its neuroscience portfolio and overall business strength.
Higher guidance indicates management's optimism and potential for earnings growth.
Apogee Acquisition Dilutes Earnings The $10.9 billion Apogee acquisition will reduce earnings by $0.14 per share in 2026 and $0.46 in 2027, with profits not expected until 2032. This near-term dilution pressures the stock.
The acquisition's dilution is a significant near-term headwind for earnings per share.
Oncology Sales Decline Oncology sales fell 2.8% as Imbruvica dropped 27.1% due to competition and IRA pricing. Newer drugs did not fully offset the decline, highlighting challenges in this segment.
The decline in oncology revenue weighs on overall growth and profitability.

Latest26 Sep – 1 Oct 2026

▲4

AbbVie's pipeline wins and new drug approvals drive growth outlook

FDA approves JUVMO for Parkinson's disease The FDA approved JUVMO (tavapadon), the first selective D1/D5 agonist for Parkinson's, with U.S. launch set for October 2026. This adds a differentiated neuroscience drug to AbbVie's portfolio, supporting future revenue growth and lifting investor confidence.
A major new drug approval directly expands AbbVie's revenue base and pipeline strength.
Zumilokibart succeeds in Phase 2 atopic dermatitis trial AbbVie's zumilokibart met the main goal in a Phase 2 study for atopic dermatitis, and the mid-dose will move into final-stage testing. This strengthens the immunology pipeline and offers a potential new treatment for a common skin condition, supporting long-term growth.
Positive mid-stage trial results advance a key pipeline candidate, signaling future revenue potential.
ABBV-295 shows promising weight loss and long half-life Phase 1 data for ABBV-295 showed up to 9.8% weight loss and an 11-12 day half-life, supporting less frequent dosing. This opens a new market for AbbVie in obesity care, a high-growth area, and could become a significant future sales driver.
Early data support a potential best-in-class obesity drug, a major new growth opportunity.
RINVOQ shows sustained vitiligo repigmentation in Phase 3 Phase 3 data show RINVOQ produced continued skin repigmentation in vitiligo through 76 weeks with no new safety issues. This supports a potential new use for a key drug, expanding its label and adding a new revenue stream if approved.
Late-stage data support a new indication for a major drug, enhancing its growth prospects.

19 Sep – 24 Sep 2026

▲3▼1

AbbVie's pipeline and label wins offset oncology and pricing headwinds

Qulipta hits Phase 3 goal in menstrual migraine Qulipta met the main goal and all secondary goals in a late-stage trial for menstrual migraine, a condition with no approved treatment. If approved, it opens a new market of over nine million U.S. patients, adding a fresh sales driver and supporting the stock.
New clinical win expands a fast-growing drug into an untapped market, a clear positive for future revenue.
Rinvoq wins EU approval for juvenile arthritis European regulators approved Rinvoq for polyarticular juvenile idiopathic arthritis, its 11th EU use. This widens the label of a key growth drug already on track for about $10.2 billion in 2026 sales, reinforcing confidence in AbbVie's immunology growth.
New regulatory approval directly expands a major growth drug's market and supports the bull case.
AI drug-discovery deals and EPKINLY approval AbbVie signed multi-year AI collaborations with Iambic and joined the AISB Bind network to speed up drug discovery, and Health Canada approved EPKINLY for relapsed follicular lymphoma. These broaden the pipeline and add a new approved use, supporting long-term growth.
New partnerships and a new approval show pipeline expansion and fresh revenue potential.
Oncology sales fall on Imbruvica and IRA pricing First-half oncology sales dropped 2.8% to $3.28 billion as Imbruvica fell 27.1% on competition and Medicare drug-price changes. Newer drugs like Venclexta and Elahere grew but did not fully offset the decline, weighing on overall growth.
A real counterweight: a key segment is shrinking due to competition and pricing pressure.

3 Sep – 17 Sep 2026

▲3▼1

AbbVie's pipeline and guidance wins offset Apogee dilution

Apogee acquisition dilutes near-term earnings AbbVie closed its $10.9 billion purchase of Apogee Therapeutics, adding an experimental immunology drug but cutting adjusted earnings by $0.14 per share in 2026 and $0.46 in 2027. Profit won't get a boost until 2032, so near-term investors see lower earnings and the stock faces pressure.
This is the main new negative event this period and directly lowers reported earnings, a key driver of the stock price.
Etentamig succeeds in Phase 3 myeloma trial AbbVie's experimental blood-cancer drug etentamig met both main goals in a late-stage trial, with a 74% response rate versus 46% for standard care and a 60% lower risk of disease worsening. This strengthens the oncology pipeline and raises hopes for a new growth driver, supporting the stock.
This is a major new clinical win that expands AbbVie's cancer franchise and improves long-term growth prospects.
Qulipta succeeds in menstrual migraine trial AbbVie's migraine drug Qulipta hit the main goal in a Phase 3 trial for menstrual migraine, reducing migraine days with a convenient dosing schedule. Qulipta sales already grew 31% to $350 million last quarter, so a new use could add revenue and lift the stock.
This is a new positive trial result that could expand the label and sales of an already fast-growing drug.
Neuroscience outlook raised on broad growth AbbVie lifted its 2026 neuroscience revenue forecast to about $12.7 billion and total revenue to roughly $67.6 billion, after first-half neuroscience sales jumped 21.8%. Strong demand across Vraylar, Botox, Qulipta, Ubrelvy and Vyalev gives investors more confidence in future profits, pushing the stock up.
This is a new guidance raise that directly improves revenue expectations and signals broad-based demand strength.

August 20261 Aug – 28 Aug 2026

▲3▼2

AbbVie's Skyrizi-Rinvoq Momentum Outweighs Pricing and Competition Risks

Skyrizi and Rinvoq Now Over 47% of Revenue AbbVie's two newer drugs, Skyrizi and Rinvoq, now make up more than 47% of total revenue and are expected to top $31 billion this year, more than offsetting declining sales of older Humira.
This shows the core growth engine replacing Humira, a key positive force for the stock.
Neuroscience Guidance Raised and Pipeline Advances AbbVie raised its neuroscience revenue guidance to about $12.7 billion, and reported promising lung cancer data plus a European filing for a subcutaneous version of Skyrizi for Crohn's disease, strengthening future growth prospects.
These pipeline and guidance updates point to new sources of revenue and expanded use of existing drugs.
Citadel Hedge Fund Boosts Stake 547% Citadel, a major hedge fund, increased its ownership stake in AbbVie by 547%, a sign that some large investors see strong value in the company despite recent concerns.
A big institutional buyer can lift sentiment and signal confidence in the stock.
Trump Demands U.S. Price Cuts Within 60 Days President Trump demanded that AbbVie cut U.S. drug prices within 60 days, threatening its pricing power and adding regulatory uncertainty that could pressure revenue and profit margins.
This is a new political risk that directly challenges AbbVie's ability to set prices in its largest market.
J&J's Oral Psoriasis Pill Wins Chinese Approval Johnson & Johnson's oral psoriasis pill Icotyde received approval in China, where 8.4 million patients could switch from injectable treatments like AbbVie's Skyrizi, posing a competitive threat in a key growth market.
This new competition could slow Skyrizi's expansion and take market share.

19 Aug – 28 Aug 2026

▲3▼1

AbbVie's pipeline and franchise expansion offset profit-guidance cut

Citadel boosts AbbVie stake by 547% Ken Griffin's Citadel bought 2.68 million more ABBV shares, a 547% increase, at an average of $214.90. A major fund raising its bet signals confidence in AbbVie's long-term value and can draw other investors in, supporting the stock price.
Large institutional buying is a fresh, concrete signal of confidence that can lift investor sentiment and demand for the shares.
New lung cancer data strengthens oncology pipeline AbbVie presented promising early data for several experimental lung cancer drugs at a major conference, with high response rates and manageable side effects. This broadens its pipeline beyond immunology and neuroscience, giving investors another potential growth engine and supporting the stock.
Fresh clinical progress on multiple oncology programs adds a new growth pillar, which can improve the long-term earnings outlook.
Skyrizi submitted for easier Crohn's dosing in Europe AbbVie asked European regulators to approve Skyrizi as a subcutaneous (under-the-skin) induction treatment for Crohn's disease, based on positive trial data. If approved, it offers patients a more convenient option and extends Skyrizi's reach, supporting future sales and the stock.
A regulatory filing that could widen a key drug's use is a concrete pipeline expansion, not just a repeat of past results.
J&J's oral psoriasis pill approved in China Johnson & Johnson won Chinese approval for Icotyde, a once-daily pill for plaque psoriasis, a market with over 8.4 million patients where AbbVie's Skyrizi competes. A convenient oral option could take share from injectables like Skyrizi, weighing on AbbVie's growth prospects in China.
This is a new competitive threat in a large market that could pressure sales of a key AbbVie drug.

1 Aug – 14 Aug 2026

▲2▼2

AbbVie's core drugs stay strong, but pricing pressure and pipeline setback weigh

Trump demands drug price cuts President Trump sent letters to major drugmakers, including AbbVie, demanding U.S. prescription price cuts within 60 days. This threatens future pricing power and revenue, pushing the stock down as investors worry about lower profits.
This is a new regulatory threat that directly pressures AbbVie's pricing and future earnings.
Skyrizi and Rinvoq fuel growth AbbVie's newer immunology drugs Skyrizi and Rinvoq now make up over 47% of total revenue, with combined sales expected to exceed $31 billion this year. Their rapid growth is replacing declining Humira sales and supports the stock's long-term value.
This shows the core business is successfully transitioning beyond Humira, a key driver of future revenue.
Neuroscience outlook raised AbbVie raised its 2026 neuroscience revenue forecast to about $12.7 billion, driven by strong sales of Vraylar, migraine drugs Ubrelvy and Qulipta, and Botox Therapeutic. This diversification adds a growing revenue stream and boosts investor confidence.
This is a new positive update showing another part of AbbVie's business is performing well and raising guidance.
Epcoritamab trial fails survival goal Genmab and AbbVie confirmed that the Phase 3 trial of epcoritamab for a type of lymphoma did not meet its main overall survival goal. This pipeline setback could delay or reduce the drug's potential, weighing on sentiment.
This is a new negative pipeline event that could hurt future oncology revenue prospects.

July 20266 Jul – 31 Jul 2026

▲3▼1

AbbVie's Q2 Beat and EU Approvals Offset by Trial Miss and Profit Guidance Cut

EU Approvals Expand Drug Labels AbbVie won European approvals for TEPKINLY in follicular lymphoma, Boey for frown lines, and RINVOQ for alopecia areata, broadening its oncology, aesthetics, and immunology offerings. These label expansions can drive future revenue growth.
New approvals are a key positive development that can boost investor confidence and future sales.
Q2 Earnings Beat and Guidance Raise AbbVie reported Q2 EPS of $3.65 and revenue of $16.99 billion, beating estimates. Management raised full-year revenue guidance by $300 million, citing strong growth in Skyrizi, Rinvoq, and neuroscience.
The earnings beat and guidance raise show operational strength and support the bull case.
Voluntary Pricing Deals Reduce Uncertainty AbbVie entered voluntary most-favored-nation pricing agreements, which lessen regulatory uncertainty around drug pricing. This proactive step may stabilize the pricing environment and reduce political risk.
Reduced regulatory uncertainty is a positive for the stock as it removes a potential overhang.
Trial Miss and Profit Guidance Cut The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint, hurting oncology sentiment. Additionally, a $291 million acquired IPR&D charge led AbbVie to cut full-year adjusted earnings guidance, sending shares down 4%.
The trial failure and earnings guidance cut are significant negatives that pressured the stock.

25 Jul – 31 Jul 2026

▲2▼2

AbbVie beats Q2, raises revenue outlook, but full-year profit guidance cut

Q2 beat and raised revenue guidance AbbVie beat Q2 estimates with $3.65 EPS and $16.99B revenue, and raised full-year revenue guidance by $300M on strong Skyrizi, Rinvoq and neuroscience growth. This shows the core business is performing well, supporting the stock's long-term value.
This is the main new positive event this period, directly driving the stock's fundamental outlook.
Full-year profit guidance lowered Despite the revenue beat, AbbVie cut its full-year adjusted earnings outlook, partly due to a $291M charge for acquired IPR&D and milestone expenses. This disappointed investors and caused shares to fall 4%, as it signals near-term profit pressure.
This is the key negative event this period, explaining the immediate stock drop and investor concern.
EU approval of RINVOQ for alopecia areata AbbVie won European approval for RINVOQ in severe alopecia areata, expanding its immunology franchise. This adds a new revenue stream and reinforces RINVOQ's growth potential, which is positive for the stock.
This is a new regulatory win that expands the market for a key drug, supporting future sales.
Epcoritamab trial setback The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint in the U.S., a setback for AbbVie's oncology pipeline. This could delay or reduce the drug's potential, weighing on sentiment.
This is a new negative pipeline event that affects future growth prospects.

6 Jul – 23 Jul 2026

▲3▼1

AbbVie's pipeline wins approvals but faces trial setback and new competition

EU approval of TEPKINLY for follicular lymphoma The European Commission approved AbbVie's TEPKINLY combination for relapsed follicular lymphoma, a chemotherapy-free option that cut progression risk by 79%. This expands AbbVie's oncology portfolio and adds a new revenue stream, supporting long-term growth.
New approval directly boosts AbbVie's oncology franchise and future sales.
EU approval of Boey for frown lines Allergan Aesthetics, part of AbbVie, won EU approval for Boey, a fast-acting botulinum toxin for frown lines. This strengthens AbbVie's aesthetics business and offers a new treatment option, potentially driving revenue growth.
New product approval expands AbbVie's aesthetics portfolio and revenue potential.
Voluntary drug-pricing deals with Trump administration AbbVie agreed to voluntary most-favored-nation pricing with the Trump administration. While this may lower prices for some drugs, AbbVie's newer immunology drugs Skyrizi and Rinvoq are expected to offset Humira's decline, and the deal reduces regulatory uncertainty.
New pricing agreement affects AbbVie's revenue but is manageable given strong new drugs.
Epcoritamab trial misses overall survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial did not meet its primary overall survival endpoint in the U.S. This setback could delay or reduce the drug's potential in this indication, weighing on sentiment.
New negative trial result directly impacts AbbVie's oncology pipeline and investor confidence.

Q2 202617 Jun – 3 Jul 2026

▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.
This major acquisition is a key new event that could drive future growth and investor sentiment.
Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.
These clinical and regulatory successes directly boosted the stock price and market value.
Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.
This regulatory risk is a new negative factor that could weigh on the stock.
Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.
Slowing growth is a fundamental concern that could limit upside for the stock.

June 202617 Jun – 3 Jul 2026

▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.
This major acquisition is a key new event that could drive future growth and investor sentiment.
Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.
These clinical and regulatory successes directly boosted the stock price and market value.
Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.
This regulatory risk is a new negative factor that could weigh on the stock.
Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.
Slowing growth is a fundamental concern that could limit upside for the stock.

17 Jun – 3 Jul 2026

▲2▼2

AbbVie hits 52-week high on Apogee deal and drug approvals, but China probe and slowing drug growth weigh

Apogee acquisition and expanded drug labels drive record high AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, adding a promising immunology drug. It also won approvals to expand Skyrizi and Rinvoq to new patient groups. These moves strengthen future growth and pushed the stock to a 52-week high, adding $43 billion in market value in a week.
This is the main reason the stock hit a new high and reflects the biggest new development this period.
US Congress opens bipartisan probe into AbbVie's China clinical trials A House committee is investigating AbbVie's clinical trials in China, including sites linked to the Chinese military and in Xinjiang. While no illegal conduct is alleged, the probe could lead to tighter oversight, higher compliance costs, and restrictions on trial locations, potentially delaying drug pipelines and hurting the stock.
This is a new risk that could negatively affect the stock and was not in earlier reports.
Growth of key drugs Skyrizi and Rinvoq shows signs of slowing Skyrizi's growth decelerated to 29.2% from 31.9%, and Rinvoq's growth slowed to 20.2% from 28.6%. These drugs are critical to AbbVie's post-Humira strategy, and any sustained slowdown could pressure the stock's valuation, which already prices in high growth.
This is a new concern about the company's growth engine that could weigh on the stock.
Positive late-stage trial results and new drug approvals bolster pipeline AbbVie reported positive Phase 3 data for venetoclax in leukemia and epcoritamab in lymphoma, and won approvals for MAVIRET in hepatitis C, SKYRIZI in pediatric psoriasis, and a new neurotoxin Boey. These advances strengthen the company's oncology and aesthetics portfolios, supporting long-term revenue growth.
These are new clinical and regulatory wins that reinforce AbbVie's pipeline and future sales potential.

20 Jun – 25 Jun 2026

▲3

AbbVie's $10.9B Apogee buy expands immunology pipeline

Apogee acquisition adds promising immunology drug AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining zumilokibart, a potential rival to Dupixent for eczema and asthma. The deal strengthens AbbVie's immunology franchise and pipeline, which investors view as a positive for long-term growth.
This is the main new event driving ABBV's stock and future prospects.
Deal funded without debt, preserving financial flexibility AbbVie will pay for Apogee entirely from operating cash flow, avoiding new debt. This keeps its balance sheet strong and reduces financial risk, which supports the stock price.
Shows the acquisition is financially manageable and not a strain.
Near-term earnings dilution, but long-term growth The deal won't add to adjusted earnings per share until 2032, so it may slightly weigh on near-term profits. However, it positions AbbVie for future growth in immunology, balancing the short-term cost with long-term benefit.
Highlights the trade-off investors are weighing.
Analysts see reasonable premium and strategic fit Citi and other analysts said the 49% premium is not excessive given Apogee's strong data and scarce immunology assets. The deal also fits with AbbVie's existing commercial infrastructure, supporting a positive view.
Analyst validation reinforces the market's positive reaction.